Fifth Third Bancorp Cuts Position in Hologic, Inc. (NASDAQ:HOLX)

Fifth Third Bancorp reduced its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 21.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,478 shares of the medical equipment provider's stock after selling 7,099 shares during the quarter. Fifth Third Bancorp's holdings in Hologic were worth $1,574,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Smithfield Trust Co grew its holdings in Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Hologic in the 4th quarter worth $49,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Trading Down 0.3%

Shares of HOLX traded down $0.17 during midday trading on Thursday, hitting $63.97. 3,239,812 shares of the stock were exchanged, compared to its average volume of 2,330,435. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The stock has a fifty day simple moving average of $59.03 and a 200 day simple moving average of $64.64. The firm has a market cap of $14.26 billion, a P/E ratio of 26.99, a P/E/G ratio of 2.35 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. Hologic's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the business posted $1.03 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In related news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.88% of the company's stock.

Analyst Ratings Changes

HOLX has been the topic of several recent research reports. Raymond James Financial reissued an "outperform" rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley reduced their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Finally, Citigroup lowered their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.